ReviewBiomedical microdevices2026
Focused ultrasound for cellular mechanoactivation and nanomedicine delivery in cancer.
Review in Biomedical microdevices, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Focused ultrasound (FUS) generates acoustic forces that activate cellular mechanotransduction, including calcium signaling via mechanosensitive ion channels, and modulates nanoparticle behavior through physical and chemical perturbations. These coupled effects have been leveraged to enhance anti-cancer drug delivery and reshape tumor transport dynamics. Integration of FUS with nanodrug systems enables coordinated modulation of vascular permeability, intratumoral distribution, and tumor microenvironment (TME) remodeling. Advanced cancer-on-a-chip platforms provide physiologically relevant in vitro models for systematically evaluating these multiscale interactions under controlled conditions. Together, these elements form an integrated framework linking FUS-induced physicochemical mechanisms to biological responses, nanoparticle behavior, and chip-based evaluation. This review presents the biological and transport-associated roles of FUS in cancer therapy, discusses its integration with nanodrug systems to modulate TME dynamics, and highlights the application of cancer-on-a-chip technologies to assess FUS-mediated transport modulation and nanodrug performance in preclinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.